← All trials
NCT04730206
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2021
- Primary completion
- May 31, 2022
- Completion date
- May 31, 2023
- First posted
- Jan 29, 2021
- Last posted
- Aug 12, 2021
- Enrollment
- 1316
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Katholieke Universiteit LeuvenLead sponsor
- Katholieke Universiteit LeuvenReponsible party - principal investigator
- University of AntwerpCollaborator
- Free University of BrusselsCollaborator
- Ghent UniversityCollaborator
- University of LiegeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.